Efficacy and Safety of Tenofovir Alafenamide (TAF) at 96 Weeks in Chronic HBV (CHB) Patients with Risk Factors for Use of Tenofovir Disoproxil Fumarate (TDF)

Basit Öğe Kaydı
dc.contributor.authorButi, Maria
dc.contributor.authorStepanova, Tatjana
dc.contributor.authorCelen, Mustafa K.
dc.contributor.authorFlisiak, Robert
dc.contributor.authorRyder, Stephen D.
dc.contributor.authorStreinu-Cercel, Adrian
dc.contributor.authorGurel, Selim
dc.date.accessioned2024-04-24T17:49:57Z
dc.date.available2024-04-24T17:49:57Z
dc.date.issued2017
dc.departmentDicle Üniversitesien_US
dc.description68th Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD) / Liver Meeting -- OCT 20-24, 2017 -- Washington, DCen_US
dc.description.abstract[Abstract Not Available]en_US
dc.description.sponsorshipAmer Assoc Study Liver Disen_US
dc.description.sponsorshipGilead; Janssen; AbbVie; Roche; Assemblypharm; Contravir; Arbutus; Sanofi; BMS; MSD/Schering-Plough; MSDen_US
dc.description.sponsorshipMaria Buti - Advisory Committees or Review Panels: Gilead, Janssen, MSD; Board Membership: Abbvie; Grant/Research Support: Gilead, Janssen; Speaking and Teaching: Gilead, Janssen, BMS; Robert Flisiak - Advisory Committees or Review Panels: AbbVie, Gilead, Merck; Consulting: AbbVie, Gilead, Merck; Grant/Research Support: AbbVie; Speaking and Teaching: AbbVie, Gilead, Merck; Fabien Zoulim - Advisory Committees or Review Panels: Janssen, Gilead, Abbvie, Arbutus, Transgene; Consulting: Roche, Contravir, Assembly; Grant/Research Support: Gilead, Roche, Assemblypharm, Janssen, Contravir, Arbutus, Sanofi; Speaking and Teaching: Gilead; Pietro Andreone - Advisory Committees or Review Panels: Intercept, Gilead, MSD/Schering-Plough, Abbvie; Grant/Research Support: BMS, MSD/Schering-Plough, Abbvie; Patrick Marcellin - Consulting: GILEAD, MSD, ABBVIE; Grant/Research Support: GILEAD, BMS, janssen, MSD, ABBVIE; Independent Contractor: GILEAD, BMS, JANSSEN, MSD, ABBVIE; Speaking and Teaching: GILEAD, BMS, MSDen_US
dc.identifier.endpage488Aen_US
dc.identifier.issn0270-9139
dc.identifier.issn1527-3350
dc.identifier.startpage488Aen_US
dc.identifier.urihttps://hdl.handle.net/11468/23114
dc.identifier.volume66en_US
dc.identifier.wosWOS:000412089801057
dc.identifier.wosqualityQ1
dc.indekslendigikaynakWeb of Science
dc.language.isoenen_US
dc.publisherWileyen_US
dc.relation.ispartofHepatology
dc.relation.publicationcategoryKonferans Öğesi - Uluslararası - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subject[No Keyword]en_US
dc.titleEfficacy and Safety of Tenofovir Alafenamide (TAF) at 96 Weeks in Chronic HBV (CHB) Patients with Risk Factors for Use of Tenofovir Disoproxil Fumarate (TDF)en_US
dc.titleEfficacy and Safety of Tenofovir Alafenamide (TAF) at 96 Weeks in Chronic HBV (CHB) Patients with Risk Factors for Use of Tenofovir Disoproxil Fumarate (TDF)
dc.typeConference Objecten_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu